Brexucabtagene Autoleucel
This page contains brief information about brexucabtagene autoleucel (Tecartus) and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Brexucabtagene autoleucel is approved to treat adults with:
- mantle cell lymphoma that has come back or does not respond to treatment
- precursor B lymphoblastic leukemia (a type of acute lymphoblastic leukemia) that has come back or does not respond to treatment
Brexucabtagene autoleucel is also being studied in the treatment of other types of cancer.
More About Brexucabtagene Autoleucel
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Brexucabtagene Autoleucel - A lay language summary of important information about this drug.
Research Results and Related Resources
Understanding the Risk of Second Cancers After CAR T-Cell Therapy
Targeted Therapy to Treat Cancer
CAR T Cells: Engineering Patients’ Immune Cells to Treat Their Cancers
Clinical Trials Accepting Patients
Find Clinical Trials for Brexucabtagene Autoleucel - Check for trials from NCI's list of cancer clinical trials now accepting patients.